RIO DE JANEIRO, BRAZIL - Bharat Biotech’s vaccine showed a 81% efficacy in preventing symptomatic COVID-19 in an interim analysis of a late-stage trial in India, it said on Wednesday, March 3rd, a major boost for the shot shunned by some health workers due to a lack of such data.
The positive result also brightens prospects for sales overseas, with the vaccine, India’s first successful home-made COVID-19 shot, already attracting interest from more than 40 countries, according to the Hyderabad-based firm.
“COVAXIN demonstrates high clinical efficacy trend against COVID-19 but also significant immunogenicity . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here